2006
DOI: 10.1038/sj.jp.7211596
|View full text |Cite
|
Sign up to set email alerts
|

Urinary excretion of darbepoetin after intravenous vs subcutaneous administration to preterm neonates

Abstract: Objective: Previous studies suggest that darbepoetin might stimulate erythropoiesis in preterm neonates more effectively if injected subcutaneously (s.c.) than if infused intravenously (i.v.). It has been postulated that this is because very high plasma concentrations after i.v. dosing result in urinary loss of the drug. However, this theory has not been tested systematically, and no direct comparisons have been made between s.c. and i.v. dosing of darbepoetin in preterm neonates.Study design: Preterm neonates… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2011
2011
2018
2018

Publication Types

Select...
5
5

Relationship

1
9

Authors

Journals

citations
Cited by 18 publications
(6 citation statements)
references
References 8 publications
0
6
0
Order By: Relevance
“…The cyclase activity of SwAAL is similar to that of PleD (k cat = 0.102 ± 0.023 s −1 ; K M = 5.8 ± 1.2 μM; k cat /K M = 0.018 s −1 μM −1 ) and lower than that of WspR (k cat = 4.50 ± 0.12 s −1 ; K M = 5.97 ± 0.80 μM; k cat /K M = 0.75 s −1 μM −1 ). 42,43 To determine the phosphodiesterase activity of SwGGAAF, we developed the first continuous assay for monitoring the enzyme activity of EAL domains. We modified a phosphate detection kit from Invitrogen by coupling it to calf intestinal phosphatase (CIP) activity.…”
Section: ■ Resultsmentioning
confidence: 99%
“…The cyclase activity of SwAAL is similar to that of PleD (k cat = 0.102 ± 0.023 s −1 ; K M = 5.8 ± 1.2 μM; k cat /K M = 0.018 s −1 μM −1 ) and lower than that of WspR (k cat = 4.50 ± 0.12 s −1 ; K M = 5.97 ± 0.80 μM; k cat /K M = 0.75 s −1 μM −1 ). 42,43 To determine the phosphodiesterase activity of SwGGAAF, we developed the first continuous assay for monitoring the enzyme activity of EAL domains. We modified a phosphate detection kit from Invitrogen by coupling it to calf intestinal phosphatase (CIP) activity.…”
Section: ■ Resultsmentioning
confidence: 99%
“…Given its significantly longer halflife, [32][33][34] darbepoetin may be the more attractive and practical choice of ESA for preterm infants. We speculate that ESAs may serve as a beneficial therapy for preterm infants, not only in acute hospitalization where the risk of anemia exists but also as possible neuroprotective agents to improve long-term neurodevelopmental outcomes.…”
Section: Figurementioning
confidence: 99%
“…It is intriguing, though, that the high-dose Darbe recipients had a median AURC 0–24 almost six times higher and two times higher than the placebo and low-dose group, respectively. Warwood et al (33) quantified Darbe clearance in the urine after subcutaneous and intravenous administration in premature infants and found no difference between the two modes of administration with negligible detectable urinary Epo. However, we infused Darbe at a much faster rate (5 min) than Warwood et al (4 h) did, perhaps achieving a much higher peak serum concentration and leading to higher urine loss.…”
Section: Discussionmentioning
confidence: 99%